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Summary
Decision-analytic models must often be informed using data which are only indirectly related to 
the main model parameters. The authors outline how to implement a Bayesian synthesis of diverse 
sources of evidence to calibrate the parameters of a complex model. A graphical model is built to 
represent how observed data are generated from statistical models with unknown parameters, and 
how those parameters are related to quantities of interest for decision-making. This forms the basis 
of an algorithm to estimate a posterior probability distribution, which represents the updated state 
of evidence for all unknowns given all data and prior beliefs. This process calibrates the quantities 
of interest against data, and at the same time, propagates all parameter uncertainties to the results 
used for decision-making. To illustrate these methods, the authors demonstrate how a previously-
developed Markov model for the progression of human papillomavirus (HPV16) infection was 
rebuilt in a Bayesian framework. Transition probabilities between states of disease severity are 
inferred indirectly from cross-sectional observations of prevalence of HPV16 and HPV16-related 
disease by age, cervical cancer incidence, and other published information. Previously, a discrete 
collection of plausible scenarios was identified, but with no further indication of which of these 
are more plausible. Instead, the authors derive a Bayesian posterior distribution, in which scenarios 
are implicitly weighted according to how well they are supported by the data. In particular, we 
emphasise the appropriate choice of prior distributions and checking and comparison of fitted 
models.
1 Introduction
Building a decision-analytic model to represent the history of disease and treatment usually 
involves choices that are based on uncertain information. The magnitude of this uncertainty 
can be quantified, but improperly quantifying uncertainty can lead to biased decisions as 
well as wrongly allocating resources for further research [1, 2]. Uncertainties in models are 
usually best characterised probabilistically: by parameterising the model flexibly [3], 
characterising each parameter by a data-derived distribution and simulating the resulting 
probabilistic model to produce a distribution for model outputs. One approach to this is 
described by the umbrella term of Bayesian evidence synthesis, which is a statistical 
framework for explicitly modelling several related and connected sources of data, and 
naturally incorporates the uncertainty in model parameters.
In particular, when the current evidence is weak or only indirectly related to the main 
parameters, it may not be straightforward to accurately represent it in the model. A crude 
approach to calibrating a model against indirect data is to informally adjust the parameters 
until predictions of key outcomes visually appear to fit observed data. For example, recent 
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models of human papillomavirus (HPV) infections [4, 5, 6] adjust parameters governing the 
transmission and natural history of HPV until models produce estimates of HPV prevalence 
which are similar to data. A more quantitative approach involves sampling model parameters 
from plausible ranges, comparing observed data to outputs from the model, and retaining a 
subset of parameters which satisfy some arbitrary standard of fit to the data, resulting in a 
range of scenarios, usually with no further indication of which are more plausible. This 
approach has been used, for example, in models of hepatitis C [7] and HPV [8, 9, 10, 11]. 
Vanni et al. [12] reviewed the choices involved in model calibration, including the 
appropriate measure of fit to the data, the algorithm to search for the best-fitting parameters, 
the standard of fit required to deem a set of parameters plausible, and methods for weighting 
the retained scenarios in probabilistic sensitivity analysis. The uncertainty about these 
choices can substantially affect the model outputs [13, 14].
1.1 Calibration as Bayesian evidence synthesis
These uncertainties can be accounted for by considering model calibration as a problem of 
Bayesian evidence synthesis. The main features of such an approach are as follows.
1. Multiple indirectly-related datasets are assumed to have been generated 
from probability distributions (“statistical models”) with parameters which 
are related to each other. Consider the simplified example in Figure 1. 
There are two datasets (A and B), each providing direct information about 
different parameters, which are known functions of the parameters of 
interest to decision-making. This is an example of a directed acyclic graph, 
explained in more detail in §3.
2. This graph forms the basis for computing the posterior probability 
distribution of the parameters. This represents the updated state of 
evidence, from combining prior beliefs and observed data using Bayes’ 
theorem. We describe this process in more detail in §3.
3. The uncertainty about the parameters of interest, expressed through this 
distribution, is then propagated through the model to generate uncertainty 
distributions for the results required for policy-making, such as life-years 
gained, infections prevented or expected costs (Figure 1).
4. The distributions of the results give appropriate weights to each parameter 
value, according to how much evidence there is in the data, thus providing 
a natural way to calibrate the model against the data.
This approach is variously referred to as multiparameter evidence synthesis [15, 16], 
generalized evidence synthesis [17], or comprehensive decision modelling [18]. This 
provides a theoretically-grounded solution to the choices discussed by Vanni et al. [12]. The 
measure of fit to the data is implicit in Bayes’ theorem, and there are standard methods for 
computing the posterior distribution (§3.4). There is no need to define an arbitrary standard 
of fit, and calibration is unified with probabilistic sensitivity analysis. For example, Goubar 
et al. [19] and Presanis et al. [20] synthesised multiple survey datasets in this way to 
estimate the prevalence of HIV infection. Whyte et al. [21] used these methods to calibrate 
the parameters of a decision model for colorectal cancer natural history, and in a model for 
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transmission of HPV, Bogaards et al. [22] used similar methods to estimate transmissibility 
and resistance to infection.
In §3 we outline the key steps of building a comprehensive Bayesian model for evidence 
synthesis, calibration and expressing uncertainty, and show how they can be applied to 
rebuilding a recently-published model for the progression of HPV infections [11], 
introduced in §2. By improving the characterisation of uncertainty in this model, we reflect 
more closely the extent of the current evidence and the potential value of further research. A 
more subtle benefit is that we reduce biases in the model outputs, since they are a non-linear 
function of the uncertain inputs [2, chapter 4]. The posterior also tells us how well the data 
confirm or modify our prior beliefs about the input parameters. We emphasise careful 
assessment of the fit of the model, potential conflicts between different sources of evidence, 
and the appropriate choice and influence of the prior distribution. Finally we discuss the 
strengths and challenges of this approach.
2 HPV progression model
Infection with HPV types 16 or 18 is associated with about 70% of cervical cancers. To 
evaluate the long-term benefits of cervical screening and vaccination against HPV, estimates 
of the natural history of HPV-related disease from initial infection to invasive cancer are 
required. A model has previously been developed [11] to estimate progression rates of HPV-
related disease, through grades of cervical intraepithelial neoplasia (CIN), to cancer. This 
was combined with transmission and economic models to evaluate policies for HPV 
vaccination in the UK [10, 23].
For the purpose of our tutorial, we investigate only the progression component. A discrete-
time Markov model is used to represent the natural history of a single HPV16 infection. This 
has a monthly cycle and 9 states, illustrated in Figure 2. The parameters we aim to estimate 
are the five progression and three regression probabilities Pij between the disease states i, j : j 
≤ 6, conditionally on the infection not clearing naturally. There were no relevant longitudinal 
data available for the UK at the time of the study from which to estimate these probabilities. 
Instead, a range of indirect cross-sectional datasets were used, listed in Table 1 together with 
the model parameters they directly inform. The principal data source is the recruitment 
phase of the ARTISTIC trial [24], which informs age-specific prevalences of HPV16 and 
HPV16-related cervical dysplasia. This is supplemented by data from the UK National 
Health Service cervical cancer screening program (NHSCCSP) [25], cancer registry data, 
national mortality statistics and published literature, as detailed in Jit et al. [11].
In Jit et al. [11], point estimates of the transition probabilities were calculated from data. The 
only expression of uncertainty was a discrete set of 54 alternative scenarios for the transition 
probabilities, otherwise these and many other uncertain parameters were assumed to be 
fixed. Here we reimplement this model as a Bayesian evidence synthesis. The scenarios and 
the fixed parameters are replaced by uncertain parameters with smooth prior distributions, 
which are updated to posterior distributions conditionally on the data. This implicitly 
weights each of the scenarios by how well they are supported by the evidence, and improves 
the characterisation of uncertainty.
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3 Building a Bayesian model for evidence synthesis
3.1 Directed acyclic graphs
In a Bayesian evidence synthesis, the “model” consists of not only a mathematical 
representation of the disease and/or treatment process (Figure 2 in this example), but also the 
network of statistical models and relationships which connect the parameters of that process 
with observed data and prior information. The basis of this approach is to build a directed 
acyclic graph or graphical model to represent these relationships, shown in Figure 3 for the 
HPV example. Quantities at the start of an arrow are assumed to “generate” the quantities at 
the end of the arrow; therefore we call these parents and children respectively. There are 
three basic types of quantity (or “node”).
a) data generated from a statistical model, whose parameters are the node’s 
parents. These are shown as bold boxes in Figure 3.
b) unknown parameters defined as deterministic functions of other parameters. 
These are shown as white boxes in Figure 3.
c) parameters with no parents, thus no arrows directed towards them in the graph. 
These are shown as dashed boxes in Figure 3. In other words, while they may 
generate data or be used in the definitions of child parameters, they are not 
defined themselves as functions of further parameters. These must be given 
prior distributions representing beliefs about their plausible values, as 
explained further in §3.3. Or if uncertainty about them is negligible, they may 
be assumed to be constant, for example, mortality rates which are estimated 
from full-population data in the HPV application.
Example (type a) In the ARTISTIC data, there are yk women diagnosed with HPV16 
infection out of nk women in several age groups k. yk arise from a binomial distribution with 
denominator nk and some probability pD(tk), assuming that each woman in the age group 
with midpoint tk has the same probability of being diagnosed with HPV16. In graphical 
model terminology, this probability and the denominator generate the observed counts, thus 
are the parent nodes. Note the distinction between (observed) data and (unknown) 
parameters. The observed prevalence is yk/nk, but the prevalence parameter is the unknown 
probability pD(tk) that an unobserved woman from the same population and age group is 
diagnosed with HPV16. Instead of including just yk/nk in the model as a constant estimate of 
the underlying prevalence, we estimate its posterior distribution to account for statistical 
uncertainty, which depends heavily on the number of women contributing to that estimate.
Example (type b) The DNA test for HPV16 used in ARTISTIC has 100% sensitivity, but is 
not always clinically relevant due to cross-reactivity between HPV types. We therefore 
express the diagnosed prevalence pD(t) as a sum of the probability pH(t) that a woman is 
truly HPV16-positive and the chance of a false positive DNA test pFP multiplied by the 
probability of being truly HPV16-negative:
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pFP is given a prior based on expert belief. Thus the false positive probability and the true 
HPV16 prevalence are the parents of the diagnosed prevalence in Figure 3.
Once nodes have been defined, they can be used in the definitions of other uncertain 
quantities required by the model. In this example, the true HPV16 prevalence pH(t) is itself 
assumed to be a non-linear function of age t (illustrated in Figure 4). This enables us to 
extrapolate prevalences observed in women aged 20-64 from ARTISTIC to younger (or 
older) ages t, which is required since the risk of infection by sexual transmission begins 
around ages 10–14, and the peak HPV16 prevalence occurs around 20 years. The unknown 
parameters governing the non-linear curve are given prior distributions, which are updated to 
posteriors given the diagnosed prevalence data yk, giving the fitted curve in Figure 4. Figure 
3 shows how these parameters, pH, pD and the model generating yk are connected through 
the graph.
3.2 Including indirect data
Indirect data can be included by adding extra nodes and arrows in the graph to define how 
the data are generated from a statistical model, and how the parameters of that model are 
related to other parameters.
Example. The transition probabilities between grades of HPV16-related neoplasia are 
largely informed by age-specific counts  of states j of cervical dysplasia observed by 
cytological screening among women diagnosed with HPV16 in ARTISTIC. These states are 
related to grades of neoplasia through parameters describing the sensitivity and specificity of 
screening, and their prevalences are also adjusted for the specificity of the test for HPV16. 
We also incorporate indirect data on these cytological state prevalences from the national 
screening programme. This gives the number of women, by age group, diagnosed in each 
state, but it is not known whether these women have any type of HPV.To include these in the 
model, we assume the counts of women (in age group k) by state arise from a multinomial 
distribution defined by a set of probabilities qjk of occupying each state j = 1, … , 5, and an 
age-specific denominator. These probabilities are an average of the prevalences among 
women diagnosed HPV16 positive  and negative , weighted by the probability of 
being diagnosed with HPV16 or not, respectively:
(1)
Thus, knowing the qjk,  and pD(tk) gives implicit information about the  to supplement 
the direct information from the HPV16-specific count data in ARTISTIC.
The remainder of the graphical model for the HPV example is set out in detail in the online 
supplement. Briefly, the transition probabilities to diagnosed (squamous cell) cervical cancer 
are informed by observed incidences from 2004 cancer registry data, adjusted to represent 
HPV16-related cases in the screened population. The transition probabilities between states 
of neoplasia are assumed to generate monthly CIN state prevalences and cancer incidences 
in a hypothetical open cohort of women infected with HPV16. These prevalence and 
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incidence parameters, after various adjustments, are assumed to generate the observed data. 
Thus, all evidence informing the model has been included in the graph, either as explicit 
data, parameters with prior distributions, or constant parameters.
Thus while decision models are typically described as being “populated” with values derived 
from data, the Bayesian approach also makes the data and its analysis an integral part of the 
model.
3.3 Specifying priors for parameters
Prior distributions must be chosen for quantities with no parents in the graph, just as in 
standard probabilistic decision modelling [2]. These may be vague or based on substantive 
information, but must represent our beliefs prior to observing the data included in the graph.
3.3.1 Vague priors—If there are sufficient data already in the model to give a precise 
estimate of a parameter, then a vague prior within plausible ranges is reasonable. With 
sufficient data, the exact choice of prior will not be influential. Though sensitivity analysis is 
advisable if the choice is uncertain or suspected to be influential (§4).
Example. The prevalences of cytological states  among women not diagnosed with 
HPV16 are given vague priors (a uniform Dirichlet distribution, as recommended in Briggs 
et al. [26]). Since we have strong information about them from the corresponding counts in 
ARTISTIC, this prior will have little influence on the results.
Parameters should be transformed to a natural scale before being given a prior, to enable 
beliefs to be expressed intuitively.
Example. Since the parameters A and C in the prevalence extrapolation model (Figure 4) 
are difficult to interpret, we use vague priors, within plausible ranges, for transformations of 
those parameters to intuitive scales: a uniform(0,1) prior for the maximum HPV16 
prevalence pmax, a uniform(0,30) prior for the age at this maximum tmax, and also a 
uniform(10,14) prior for the minimum age of infection t0. Assuming the prevalence for the 
oldest women B = 0 for the purpose of deriving these priors, these give C = n/(tmax − t0) and 
A = pmax exp(n)(n/C)−n. To replace the discrete scenarios used in [11] with a continuous 
distribution, we place a uniform(1,2) prior on the polynomial order n. These priors are all 
very vague compared with the information in the data — see Figure 6 for the corresponding 
posteriors.
3.3.2 Informative priors—If there are no direct data to inform a parameter, informative 
priors could be derived from published literature or from expert beliefs, ideally formally 
elicited [27]. When the priors are updated to posteriors, we can assess how much the data 
confirm or modify our substantive beliefs.
Example. We enhance the original analysis of Jit et al. [11] by incorporating prior 
knowledge about the transition probabilities between grades of neoplasia in the presence of 
HPV16 (Pij : j ≤ 6). These are derived from a systematic review of HPV natural history by 
Insinga et al. [28], which did not include Jit et al. [11]. This presents annual probabilities, 
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with the number of patients and denominators N used to obtain them, for four out of the 
eight transitions. These were converted to monthly probabilities and corresponding monthly 
counts y by assuming a constant transition rate within the year. This gives Beta(y + 1, N − y 
+ 1) prior distributions for the monthly probabilities [2, 29], illustrated in Figure 5. The 
other four transition probabilities were given uniform(0,1) priors. Any correlations between 
different parameters should be acknowledged in decision models [30]; we assume prior 
independence between the probabilities, but if any correlations are plausible, given the data, 
these will appear in the posterior.
Example. For the sensitivities and specificities of cytological screening and the false 
positive rate of the HPV16 test, pFP , we used uniform or Beta priors whose bounds or 
quantiles were chosen to cover the discrete scenarios previously presented in the analysis of 
Jit et al. [11]. The priors were independent given the lack of published information about any 
correlations.
3.4 Computing the posterior distribution
Once all quantities in the graph have been defined or given priors, the joint posterior 
distribution of all unknowns will be calculated, which may include quantities of direct 
interest to a decision maker, such as the incremental net benefit of an intervention. The 
decision then allows for the parameter uncertainty in all model inputs, and includes the 
evidence from the calibration data. In other words, probabilistic sensitivity analysis and 
model calibration are performed simultaneously.
The graph shows how the underlying parameters of interest — in Figure 3, the transition 
probabilities Pij between disease states i, j — can be informed simultaneously from several 
data sources. Learning about the posterior of a parameter can occur “both ways” along 
arrows. For example (§3.2) the posterior distribution of the HPV16-positive cytological state 
prevalences  is derived directly from the corresponding ARTISTIC data , but is also 
influenced by its three parent parameters and their own ancestors and descendants, and by its 
other children, the HPV16-unknown cytological state prevalences qjk, which are inferred 
from the national screening programme. The posterior distribution of the transition 
probabilities thus depends directly on its prior, but also indirectly on all data and on the 
priors of all other parameters.
3.4.1 Markov Chain Monte Carlo—Bayes’ theorem states that the joint posterior 
distribution (probability density) p(θ|x) of the set of unknowns in the model θ given all data 
x is proportional to the (joint) prior p(θ) multiplied by the sampling distribution of data 
given parameters p(x|θ) (often called the likelihood). However the constant of 
proportionality, and summaries of the resulting posterior, are generally too complex to be 
calculated directly. Instead, the graphical model structure gives a basis for an iterative 
Markov Chain Monte Carlo (MCMC) algorithm to generate samples from the posterior 
distribution. The distribution can be expressed as the product  of all 
distributions of individual nodes υ, each conditional on its parents pa[υ] [31].
• Initial values are chosen for all υ.
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• New values are then sampled from the full-conditional distributions p(υ|.) 
of each node υ in turn, where . indicates the current values of all nodes 
other than υ. Each full-conditional distribution can be simplified as the 
product of the prior distribution and the distributions of all children of υ:
Through the distributions of the children (the likelihood) any data directly 
or indirectly generated by υ will contribute to the posterior of υ.
• Each iteration consists of one sample from the full set of nodes θ. After an 
initial sequence of “burn-in” iterations, the algorithm will converge (under 
weak conditions, see Gilks et al. [31]) such that the samples will 
eventually be drawn from the true joint posterior distribution.
3.4.2 The BUGS language and software—The BUGS language [32] allows 
graphical models to be expressed in a text format. In brief, each node’s definition, as a 
deterministic or random function of its parent parameters, corresponds to a language 
statement. For example, the definitions of yk and pD (tk) in §3.1 are written as
for (k in 1:Nage){
  y[k]      ~ dbin(pD[k], n[k])
  pD[k] <- pH[k] + pFP*(1 - pH[k])
}
The software then constructs the graphical model internally, and chooses and implements 
appropriate methods to draw random numbers from the full-conditional distribution of each 
node. An extensive guide to Bayesian modelling using the BUGS language and software is 
given by Lunn et al. [29], and Welton et al. [16] give a practical guide to its use in health 
decision modelling. The full BUGS model code representing the definitions in this example 
is provided in an online supplement. For this application, we use the JAGS software for 
BUGS language interpretation and computation [33]. Implementation in WinBUGS or 
OpenBUGS [32] would have been equally feasible.
4 Model checking and sensitivity analysis
Although a Bayesian graphical model is a natural framework for evidence synthesis, it can 
still involve many assumptions which should be questioned.
• A model can be assessed by checking and comparing the fit of model 
predictions to the data used to build it [34], then improving the model if 
necessary (“internal” [35] or “dependent ” [36] validation).
• Where more than one dataset informs a quantity of interest, any potential 
inconsistency or conflict must be investigated [16, 20].
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• We recommend that any relevant data are included in the graphical model, 
rather than held back for external validation. Judgement is needed here, 
since modifying the model to accommodate increasingly less relevant 
evidence will make it increasingly cumbersome and prone to 
misspecification. If it is uncertain whether some data are relevant, perhaps 
due to differences in population characteristics or clinical practice, 
sensitivity analysis should be undertaken.
• When the evidence informing a particular part of the model is weak, so 
that different reasonable choices of prior distribution may affect the 
results, these should be compared in sensitivity analysis. Sensitivity 
analyses may also show the relative influence of the prior and the data on 
the conclusions.
• Relative fit between alternative Bayesian models can be compared with 
the posterior mean deviance [as in 20] or the deviance information 
criterion (DIC), which is an estimate of the ability to predict a replicate 
dataset [37, 38].
Note that the Bayesian approach does not eliminate the need for discrete sensitivity analyses 
for the parts of the model that are poorly informed by data, but the number of scenarios can 
be greatly reduced if these are replaced wherever possible by smooth priors, as in the HPV 
example.
In the next sections, we explain how these checks were carried out in the example, and led to 
refinements of the model. In Figure 5, the prior and posterior distributions of the five state 
progression and regression probabilities are illustrated under the model as described, and 
four other assumptions explained below. This also shows the estimates from the scenarios 
considered in Jit et al. [11] — note that there are some extreme scenarios which are 
implausible, thus have negligible weight in the posterior. The only substantial posterior 
correlation (ρ > 0.5) was between the progression/regression probabilities to/from CIN3. 
The only substantial inverse correlation (ρ < −0.5) was between the CIN3→pre-cancer and 
pre-cancer→diagnosed cancer transition probabilities, due to there being few observations in 
the pre-cancer state.
4.1 Model checking and accommodating conflicts
Firstly in the HPV example, we graphically compare the posterior distribution for the 
cytological state prevalences ,  to the corresponding observed prevalences from the 
ARTISTIC data. The posterior from the model as described so far (labelled “conflicted 
model”) is estimated not only from ARTISTIC, but also from the national screening 
programme through Equation (1). Figure 7 illustrates that this model does not fit the 
ARTISTIC data well, as the observed prevalences are only just within the 95% posterior 
credible limits, both for women with and without HPV16 diagnoses. This suggests that the 
ARTISTIC and national data are providing conflicting information to this part of the model, 
such that the two datasets do not agree on the proportions of women in the same age group 
being in various states.
Jackson et al. Page 9
Med Decis Making. Author manuscript; available in PMC 2016 April 27.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
We accommodate this conflict by assuming that the odds of being in states CIN1 or higher 
for a HPV16-negative woman in the ARTISTIC data is a constant multiplier of the 
corresponding odds in the national data. This constant is estimated as part of the model. This 
produces a much better fit in Figure 7 (model labelled “base case”). This supposes that 
women selected for ARTISTIC have slightly different prevalences of non-HPV16-related 
neoplasia from the general population. The prevalences of HPV16-related disease might also 
be different, but we assume these are the same given that the adjustment we have made 
produces an adequate fit. All subsequent results we present are from this model unless stated 
otherwise. Both the progression probability to CIN1 and the corresponding regression rate 
are changed after resolving this conflict (Figure 5). Other datasets are fitted reasonably well 
by the posterior distributions (not shown).
Note that the posterior distributions for  (bottom half of Figure 7) are smooth functions of 
age, because the prior information about these prevalences, which comes indirectly from all 
other data sources in the model via the Markov transition probabilities, “shrinks” each 
individual data point towards the prior mean.
4.2 Sensitivity to data inclusion
There is also doubt about whether the national screening data are worth including at all, 
given that state prevalences by HPV16 presence are observable from ARTISTIC alone, and 
HPV16 presence is not recorded in the national data. While including it may improve the 
precision of inferences from ARTISTIC alone, there is the risk of other implicit, conflicting 
information “feeding back” through the graph and affecting other parameter estimates, for 
example the HPV16 prevalences. We therefore compare the results under a third model 
(labelled “No NHSCCSP data”), where these data and the HPV16-negative data from 
ARTISTIC (which are only required to understand the contribution of non-HPV16 related 
dysplasia to the prevalences of dysplasia in the national data) are excluded. The estimated 
transition probabilities do not substantially change, see Figure 5. However, the posterior 
distribution of the maximum HPV16 prevalence (Figure 4) is shifted upwards by a couple of 
percentage points, accounting better for the observations from around age 20. This suggests 
that the national data are feeding back to this part of the model.
Since we would expect the national screening programme to better represent the distribution 
of states than ARTISTIC which is a smaller, regionally-biased sample of women consenting 
to participate, our base case results are those which do include the national data. In general, 
if the model is used to evaluate a policy for the population, any relevant full population data 
should be included, particularly since the highly selected populations typically included in 
randomised trials may not represent the patients of interest.
4.3 Sensitivity to prior assumptions
As well as the two alternative models which use the national screening data differently, we 
performed a further two sensitivity analyses. The first investigates how much the posterior 
distributions of the transition probabilities were affected by the strong priors, compared to 
the data. We downweighted the contribution of the prior distributions by making them 
substantially weaker, arbitrarily multiplying their variances by 10. Note that completely 
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vague Uniform(0,1) priors on all probabilities were not practicable, since they resulted in 
MCMC convergence failure, but more importantly they would not have really represented 
our prior beliefs in this case — for instance values over 0.5 for the monthly progression 
probability would be deemed highly unrealistic beforehand. Under the weaker priors, the 
posterior distributions of the CIN1→CIN2 and CIN2→CIN1 probabilities became more 
widely dispersed. The posterior means of the other parameters were unchanged, and the 
posterior variances were only slightly inflated, suggesting that the stronger prior merely adds 
precision to the study data rather than shifting estimates away from the data. The exception 
is the regression rate from CIN1 to (CIN-free) HPV16, where the study data appear to 
support lower values of this probability than the prior. The base case model compromises 
between prior and data through Bayes’ theorem.
The other key uncertain parameters describe the accuracy of the cytological screening tests. 
The information about these came from a review of a very heterogeneous range of studies. 
Therefore we performed another analysis where all sensitivities and specificities are fixed at 
100%, one of the extreme scenarios considered in Jit et al. [11]. The posterior distributions 
for many of the transition probabilities (Figure 5) changed, confirming that they are sensitive 
to the screening accuracies. In particular, the posterior variances are smaller when these 
probabilities are fixed. The fit of this model is also much poorer than the base case, judging 
from DIC and plots (not shown). Information about the screening accuracies also comes, 
very indirectly, from the data (through Figure 3). This results in posteriors (Figure 6) which 
are reasonably precise compared to the diffuse priors, and indicate the strength of evidence 
in the data for each value within the prior bounds. There is a moderate posterior correlation 
(ρ = 0.43) between the sensitivity and specificity of detecting CIN1, but no other notable 
correlation. The specificity of the test to identify HPV16 DNA had been given a fairly strong 
prior (median 0.9975%), which is slightly modified by the data (posterior median 0.9984%).
5 Discussion
Bayesian graphical modelling is a useful framework for including all policy-relevant 
evidence in a decision model, even evidence which is only indirectly related to the main 
parameters. We have outlined the key steps of this approach, and demonstrated how we used 
it to obtain posterior distributions for progression and regression probabilities of HPV16-
related cervical neoplasia. The posterior gives a more accurate reflection of the available 
evidence than the scenario analyses used in previous HPV models, by also including the 
evidence about how plausible each scenario was, and reducing bias due to ignoring some 
parameter uncertainties. A single posterior distribution is also easier to interpret.
These methods are complex, but necessarily so in the HPV example, and only require a 
similar amount of programming to the original implementation. The principles of Bayesian 
statistical modelling are widely applicable in health policy evaluation [17, 16]. The BUGS 
language and software can provide the posterior distribution of any Bayesian model in 
principle, though models with very large numbers of unknowns, such as this one, require 
custom extensions to the software to be written in more low-level programming languages. 
Whyte et al. [21] also describe a similar implementation of a Bayesian health economic 
model using Visual Basic within Excel.
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The HPV model could be extended as in Jit et al. [10, 23] to incorporate an infection and 
economic model to evaluate policies for HPV vaccination. This was originally based on over 
a thousand alternative scenarios which met a certain standard of fit, but with no measure of 
relative plausibility between them. A Bayesian reimplementation to formally characterise 
this uncertainty would be expected to have a similar computational burden to the original 
approach, as was the case for the progression-only component. However this is likely to 
raise more uncertainties due to weak evidence, for example, about transmission, infection, 
and natural clearance, and potential conflicts with other data sources in the model. It is 
therefore unclear how much benefit would be gained from greater statistical formality in this 
example. As a graphical model becomes more complex, there is greater potential for 
erroneous information from one part of the model to indirectly give bias in another part. 
There is ongoing research on controlling the propagation of information in graphs through 
restrictions variously termed “cutting feedback” [39] or “modularisation” [40].
No statistical method can eliminate uncertainty in a model, since evidence is always limited. 
A decision model should synthesise all relevant evidence, but judgements must always be 
made about what evidence is sufficiently relevant or strong. Potential conflicts between two 
sources of data on the same quantity should be investigated and explained, leading to 
refinements in the model [20]. In general, for more complex models, careful validation and 
sensitivity analysis become more important (§4).This was demonstrated in the HPV 
example, where, after examining plots of model fit, some model assumptions were relaxed 
to accommodate the population screening data.
Weak evidence about some component of a Bayesian model will result in sensitivity of the 
results to the prior distribution. Conversely, if prior sensitivity is detected, this indicates 
areas where stronger data or further research are required. In the HPV model, for example, 
there was substantial uncertainty around the accuracy of cervical screening. While the prior 
that we used was based on the best available information, sensitivity analysis showed that 
these parameters were influential. Although a posterior distribution gives a better 
representation of the data than a range of scenarios, a limited number of sensitivity analyses 
are still useful to show how the results would be affected if the evidence were to change. If 
this model had been employed for decision-making, formal “value of information” methods 
[see, e.g. 41] could be used to predict for which parameters more research would give the 
greatest expected benefits.
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Acknowledgements
This work was supported by the Medical Research Council [Unit Programme numbers U015232027, U105260566]. 
The funding source had no role in the study which was the authors’ independent work.
References
1. Claxton K, Sculpher M, Drummond M. A rational framework for decision-making by the National 
Institute for Clinical Excellence (NICE). Lancet. 2002; 360(9334):711–715. [PubMed: 12241891] 
Jackson et al. Page 12
Med Decis Making. Author manuscript; available in PMC 2016 April 27.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
2. Briggs, A.; Sculpher, M.; Claxton, K. Decision modelling for health economic evaluation. 
Handbooks in Health Economic Evaluation. Oxford University Press; Oxford: 2006. 
3. Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing 
structural uncertainty in decision models. Medical Decision Making. 2011; 31(4):662–674. 
[PubMed: 21602487] 
4. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human 
papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness 
analysis. Cost Effectiveness and Resource Allocation. 2008; 6(4)
5. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 
16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling 
analyses. PLoS Medicine. 2006; 3(5):e138. [PubMed: 16573364] 
6. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. 
Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the 
burden of cervical cancer in the UK. British Journal of Cancer. 2006; 96(1):143–150. [PubMed: 
17146475] 
7. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C 
virus infection in the United States. American Journal of Epidemiology. 2002; 156(8):761–773. 
[PubMed: 12370165] 
8. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical 
cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. Journal of 
the National Cancer Institute. 2008; 100(5):308–320. [PubMed: 18314477] 
9. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ. Multiparameter 
calibration of a natural history model of cervical cancer. American Journal of Epidemiology. 2007; 
166(2):137–150. [PubMed: 17526866] 
10. Jit M, Choi Y-H, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the 
United Kingdom. British Medical Journal. 2008; 337(a769)
11. Jit M, Gay N, Soldan K, Choi YH, Edmunds WJ. Estimating progression rates for human 
papillomavirus infection from epidemiological data. Medical Decision Making. 2010; 30(1):84–
98. [PubMed: 19525483] 
12. Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, Legood R. Calibrating models in 
economic evaluation: a seven-step approach. Pharmacoeconomics. 2011; 29(1):35–49. [PubMed: 
21142277] 
13. Taylor DCA, Pawar V, Kruzikas DT, Gilmore KE, Sanon M, Weinstein MC. Incorporating 
calibrated model parameters into sensitivity analyses: Deterministic and probabilistic approaches. 
Pharmacoeconomics. 2012; 30(2):119–126. [PubMed: 22149631] 
14. Karnon J, Vanni T. Calibrating models in economic evaluation: a comparison of alternative 
measures of goodness of fit, parameter search strategies and convergence criteria. 
Pharmacoeconomics. 2011; 29(1):51–62. [PubMed: 21142278] 
15. Ades AE, Sutton AJ. Multiparameter evidence synthesis in epidemiology and medical decision-
making: current approaches. Journal of the Royal Statistical Society: Series A (Statistics in 
Society). 2006; 169(1):5–35.
16. Welton, NJ.; Sutton, AJ.; Cooper, NJ.; Abrams, KR.; Ades, AE. Evidence Synthesis for Decision 
Making in Healthcare. Wiley; Chichester: 2012. 
17. Spiegelhalter, DJ.; Abrams, KR.; Myles, JP. Bayesian approaches to clinical trials and health-care 
evaluation. Wiley; Chichester, U.K: 2004. 
18. Cooper NJ, Sutton AJ, Abrams KR, Turner D, Wailoo A. Comprehensive decision analytical 
modelling in economic evaluation: a Bayesian approach. Health Economics. 2004; 13(3):203–226. 
[PubMed: 14981647] 
19. Goubar A, Ades AE, DeAngelis D, McGarrigle CA, Mercer CH, Tookey PA, Fenton K, Gill ON. 
Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on 
Bayesian multiparameter synthesis of surveillance data. Journal of the Royal Statistical Society: 
Series A (Statistics in Society). 2008; 171(3):541–580.
20. Presanis AM, De Angelis D, Spiegelhalter DJ, Seaman S, Goubar A, Ades AE. Conflicting 
evidence in a Bayesian synthesis of surveillance data to estimate human immunodeficiency virus 
Jackson et al. Page 13
Med Decis Making. Author manuscript; available in PMC 2016 April 27.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
prevalence. Journal of the Royal Statistical Society: Series A (Statistics in Society). 2008; 171(4):
915–937.
21. Whyte S, Walsh C, Chilcott J. Bayesian calibration of a natural history model with application to a 
population model for colorectal cancer. Medical Decision Making. 2011; 31(4):625–641. 
[PubMed: 21127321] 
22. Bogaards JA, Xiridou M, Coupé VMH, Meijer CJLM, Wallinga J, Berkhof J. Model-based 
estimation of viral transmissibility and infection-induced resistance from the age-dependent 
prevalence of infection for 14 high-risk types of human papillomavirus. American Journal of 
Epidemiology. 2010; 171(7):817. [PubMed: 20231211] 
23. Jit M, Chapman R, Hughes O, Choi Y-H. Comparing bivalent and quadrivalent human 
papillomavirus vaccines: economic evaluation based on transmission model. British Medical 
Journal. 2011; 343:d5775. [PubMed: 21951758] 
24. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A, Peto J. HPV 
testing in routine cervical screening: cross sectional data from the ARTISTIC trial. British Journal 
of Cancer. 2006; 95(1):56–61. [PubMed: 16773068] 
25. Department of Health. England: 2005-2006. Cervical Screening Programme, England, 2005-2006. 
Available from http://www.ic.nhs.uk/pubs/csp0506
26. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple 
branches: use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making. 
2003; 23(4):341–350. [PubMed: 12926584] 
27. O’Hagan, A.; Buck, C.; Daneshkhah, A.; Eiser, JR.; Garthwaite, P.; Jenkinson, D.; Oakley, J.; 
Rakow, T. Uncertain Judgements: Eliciting Experts’ Probabilities. Statistics in Practice. Wiley; 
2006. 
28. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of 
Human Papillomavirus(HPV) Disease: a critical and systematic review of the literature in the 
development of an HPV dynamic transmission model. BMC Infectious Diseases. 2009; 9(1):119. 
[PubMed: 19640281] 
29. Lunn, D.; Jackson, C.; Best, N.; Thomas, A.; Spiegelhalter, D. The BUGS Book: A Practical 
Introduction to Bayesian Analysis. CRC Press / Chapman and Hall; 2012. 
30. Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic 
sensitivity analysis. Health Economics. 2006; 15(4):373–381. [PubMed: 16389628] 
31. Gilks, WR.; Richardson, S.; Spiegelhalter, DJ. Markov Chain Monte Carlo in Practice. Chapman 
and Hall; London: 1996. 
32. Lunn DJ, Thomas A, Best NG, Spiegelhalter DJ. Win-BUGS - a Bayesian modelling framework: 
Concepts, structure, and extensibility. Statistics and Computing. Oct; 2000 10(4):325–337.
33. Plummer, M. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. 
In: Hornik, Kurt; Leisch, Friedrich; Zeileis, Achim, editors. Proceedings of the 3rd International 
Workshop on Distributed Statistical Computing; Vienna, Austria. 2003. http://www.ci.tuwien.ac.at/
Conferences/DSC-2003/Proceedings/ ISSN 1609-395X
34. Gelman, A.; Carlin, JB.; Stern, HS.; Rubin, DB. Bayesian Data Analysis. second edition. Chapman 
and Hall; London: 2003. 
35. Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health 
Economics. 2009; 19(1):43–55. [PubMed: 19206080] 
36. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and 
validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working 
Group, part 4. Medical Decision Making. 2012; 32:733–743. [PubMed: 22990088] 
37. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity 
and fit (with discussion). Journal of the Royal Statistical Society, Series B. 2002; 64(4):583–639.
38. Plummer M. Penalized loss functions for Bayesian model comparison. Biostatistics. 2008; 9(3):
523–539. [PubMed: 18209015] 
39. Lunn D, Best N, Spiegelhalter D, Graham G, Neuenschwander B. Combining MCMC with 
sequential PK/PD modelling. Journal of Pharmacokinetics and Pharmacodynamics. 2009; 36(1):
19–38. [PubMed: 19132515] 
Jackson et al. Page 14
Med Decis Making. Author manuscript; available in PMC 2016 April 27.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
40. Liu F, Bayarri M, Berger J. Modularization in Bayesian analysis, with emphasis on analysis of 
computer models. Bayesian Analysis. 2009; 4(1):119–150.
41. Welton NJ, Ades AE, Caldwell DM, Peters TJ. Research prioritization based on expected value of 
partial perfect information: a case study on interventions to increase uptake of breast cancer 
screening. Journal of the Royal Statistical Society, Series A. 2008; 171(4):807–841.
42. Munoz N, Bosch FX, Castellsague X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer 
CJLM. Against which human papillomavirus types shall we vaccinate and screen? The 
international perspective. International Journal of Cancer. 2004; 111(2):278–285. [PubMed: 
15197783] 
43. Redburn JC, Murphy MFG. Hysterectomy prevalence and adjusted cervical and uterine cancer 
rates in England and Wales. BJOG: An International Journal of Obstetrics & Gynaecology. 2001; 
108(4):388–395. [PubMed: 11305546] 
44. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy 
of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities. Annals 
of Internal Medicine. 2000; 132(10):810–819. [PubMed: 10819705] 
45. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared 
with conventional cervical cytology: a systematic review and meta-analysis. Obstetrics & 
Gynecology. 2008; 111(1):167. [PubMed: 18165406] 
Jackson et al. Page 15
Med Decis Making. Author manuscript; available in PMC 2016 April 27.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1: 
Illustration of decision model calibration as a directed acyclic graph. “Nodes” at the start of 
an arrow (parents) are assumed to “generate” the nodes at the end of the arrow (children). 
Bold-bordered boxes represent observed data. The white boxes are quantities which are 
defined as explicit functions of other parameters. The dashed boxes represent quantities 
which cannot be defined this way, thus are given prior distributions (see Section 3.1).
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Figure 2: 
Markov model for natural history of HPV16 infection – states of cervical neoplasia and 
permitted monthly transitions with associated probabilities. Progression to treatment, death 
and hysterectomy is allowed from all states up to pre-cancer.
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Figure 3: 
Directed graphical model for evidence synthesis to estimate transition probabilities between 
states of HPV16 infection. Notation as in Figure 1.
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Figure 4: 
Prevalences of diagnosed HPV16 infection among women in ARTISTIC (2006) data and 
extrapolation to younger women — observed and model posterior 95% credible intervals. 
Since the specificity is over 99%, this also illustrates the approximate trajectory of the true 
prevalence, pH, related to age t as pH(t) = B + exp(−C(t − t0))(A(t − t0)n − B) (see Section 
3.3).
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Figure 5: 
Prior and posterior distributions of monthly transition probabilities between states of HPV16 
infection (note some axis limits are extended), compared with scenarios from Jit et al. 
(2010). The darkness of each strip is proportional to the posterior density, fading to white at 
zero density, with 95% credible limits.
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Figure 6: 
Prior distributions (thin lines) and posterior distributions (thicker strips with darkness 
proportional to probability density, and 95% credible limits) for cytological screening 
accuracies, HPV16 test specificity and parameters of the model for extrapolating HPV16 
prevalence.
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Figure 7: 
Prevalences of cervical dysplasia among women in ARTISTIC (2006) data by HPV16 
diagnosis — observed data and posterior distributions (median and 95% credible interval) 
under base case and conflicted models.
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Table 1:
HPV model parameters and associated data sources. See Figure 3 for how these are connected in a graphical 
model.
    Parameter
Informed by direct data
Data source Age groups k
    Cytological state j prevalence in age
    group k (HPV16 positive women):q jk
+
    Cytological state prevalence (HPV16
    negative women):q jk
−
    HPV16 prevalence at age tk: pH (tk)
    Cytological state prevalence (HPV
    presence unknown): qjk
    Squamous cell cervical cancer incidence: pk
C
    HPV type distribution in cervical cancer: pk
16
    Screening and treatment rates: Pi7(t)
    Mortality rates at age t: (Pi8(t), common
     to all CIN states i)
    Hysterectomy rates (for reasons
    unrelated to cervical disease) Pi9(t)
ARTISTIC(y jk
+
, yk)
ARTISTIC(y jk
− , nk − yk)
ARTISTIC (yk, nk)
NHS cervical
cancer screening
programme(y jk
N , nk
N)
Office for National
Statistics, England
[2004] (nk
C,Nk
C)
Munoz et al. [42]
Various, see [11]
Office for National
Statistics, England and
Wales [2003]
Redburn and Murphy
[43]
Annually
20–35, 5-yearly
35–55, 55–64
Under 20, 5-yearly
20–74, 75+
Yearly 10–89
<35, 35–49, ≥50
Screening rates 0–
20, 5 yearly to 80
Yearly 10–90
10–20, 5 yearly to
80, 80–90
Informed by indirect data above and given informative priors
                                                                       Prior source
    Transition probabilities Pij between
    CIN states i, j : j ≤ 6:
    Specificity of HPV16 test: 1 − pFP
    Accuracy of cervical screening: S
Insinga et al. [28]
Expert belief [see 11]
Nanda et al. [44], Arbyn et al. [45]
Independent of
age
Key intermediate quantities — defined as functions of other parameters
    HPV16 prevalence at age t under 20
    years (predicted): pH (t)
    CIN state j prevalence: pj (t)
Monthly 10–90
Monthly 10–90
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